Sol Gel Technologies Ltd (NASDAQ:SLGL) — Market Cap & Net Worth
Market Cap & Net Worth: Sol Gel Technologies Ltd (SLGL)
Sol Gel Technologies Ltd (NASDAQ:SLGL) has a market capitalization of $233.72 Million ($233.72 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15948 globally and #3609 in its home market, demonstrating a 4.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sol Gel Technologies Ltd's stock price $75.61 by its total outstanding shares 3245270 (3.25 Million). Analyse cash efficiency ratio of Sol Gel Technologies Ltd to see how efficiently the company converts income to cash.
Sol Gel Technologies Ltd Market Cap History: 2018 to 2026
Sol Gel Technologies Ltd's market capitalization history from 2018 to 2026. Data shows growth from $19.54 Million to $245.37 Million (23.07% CAGR).
Index Memberships
Sol Gel Technologies Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #431 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1548 of 3165 |
Weight: Sol Gel Technologies Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sol Gel Technologies Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sol Gel Technologies Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.05x
Sol Gel Technologies Ltd's market cap is 7.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $19.54 Million | $129.00K | -$32.20 Million | 151.45x | N/A |
| 2019 | $55.66 Million | $22.90 Million | -$24.61 Million | 2.43x | N/A |
| 2020 | $31.77 Million | $8.77 Million | -$27.40 Million | 3.62x | N/A |
| 2021 | $24.01 Million | $31.27 Million | $3.22 Million | 0.77x | 7.46x |
| 2022 | $14.80 Million | $3.88 Million | -$14.92 Million | 3.81x | N/A |
| 2023 | $3.59 Million | $1.55 Million | -$27.24 Million | 2.31x | N/A |
| 2024 | $3.02 Million | $11.54 Million | -$10.58 Million | 0.26x | N/A |
| 2025 | $136.76 Million | $19.39 Million | -$6.13 Million | 7.05x | N/A |
Competitor Companies of SLGL by Market Capitalization
Companies near Sol Gel Technologies Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Sol Gel Technologies Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sol Gel Technologies Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Sol Gel Technologies Ltd's market cap moved from $19.54 Million to $ 245.37 Million, with a yearly change of 23.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $245.37 Million | +79.43% |
| 2025 | $136.76 Million | +4430.70% |
| 2024 | $3.02 Million | -15.83% |
| 2023 | $3.59 Million | -75.77% |
| 2022 | $14.80 Million | -38.38% |
| 2021 | $24.01 Million | -24.41% |
| 2020 | $31.77 Million | -42.92% |
| 2019 | $55.66 Million | +184.88% |
| 2018 | $19.54 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Sol Gel Technologies Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $233.72 Million USD |
| MoneyControl | $233.72 Million USD |
| MarketWatch | $233.72 Million USD |
| marketcap.company | $233.72 Million USD |
| Reuters | $233.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more